← Eichor
Condition: Alk Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Alk

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Phase 2 · 1 location(s) · New York Medical College · NCT07013565Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Phase 3 · 1 location(s) · Tata Memorial Hospital · NCT05236946Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib
Phase N/A · 1 location(s) · Centro de Tratamiento e Investigación sobre Cáncer, Luis Car · NCT07633626ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06426511Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT04322890Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia
Phase 3 · 1 location(s) · Queen Mary Hospital, Hong Kong · NCT06643416Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Ef
Phase 2 · 1 location(s) · Xinqiao Hospital of Chongqing · NCT06953843Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Phase 1/Phase 2 · 2 location(s) · Princess Maxima Center for Pediatric Oncology · NCT04925609Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Phase 3 · 162 location(s) · Children's Oncology Group · NCT03126916Post Marketing Surveillance(PMS) Study of Lorviqua in Korea
Phase N/A · 1 location(s) · Pfizer · NCT05599412A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Ac
Phase 1/Phase 2 · 74 location(s) · Nuvalent Inc. · NCT05384626Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer
Phase N/A · 1 location(s) · Jinming Yu · NCT05991895Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Pres
Phase 2 · 27 location(s) · Groupe Francais De Pneumo-Cancerologie · NCT06620835A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic
Phase 3 · 296 location(s) · AstraZeneca · NCT06868277Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT05266846Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT06176690Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06234579International Rare Histiocytic Disorders Registry (IRHDR)
Phase N/A · 15 location(s) · The Hospital for Sick Children · NCT02285582Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06221670A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advance
Phase 3 · 287 location(s) · AstraZeneca · NCT06627647ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT05014464Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)
Phase 1/Phase 2 · 1 location(s) · Tang-Du Hospital · NCT07354061A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment o
Phase 2 · 1 location(s) · Xinqiao Hospital of Chongqing · NCT06947694QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
Phase 2 · 1 location(s) · Anhui Provincial Cancer Hospital · NCT07330596Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C
Phase 2 · 7 location(s) · Mayo Clinic · NCT06834373Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT05284539A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Pos
Phase 1/Phase 2 · 33 location(s) · Hoffmann-La Roche · NCT04774718A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Phase 1/Phase 2 · 12 location(s) · TRIANA Biomedicines, Inc. · NCT07491497Gilteritinib for the Treatment of ALK NSCLC
Phase 1 · 3 location(s) · University of Michigan Rogel Cancer Center · NCT06225427
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.